Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP) (FAMPAP)

• ClinicalTrials.gov Identifier: NCT01511068
• Recruitment Status: Completed
• First Posted: January 18, 2012
• Results First Posted: September 1, 2020
• Last Update Posted: September 1, 2020
• Sponsor: Children's Hospital Medical Center, Cincinnati
• Collaborators: Virginia Commonwealth University; Genzyme, a Sanofi Company
• Information provided by (Responsible Party): Children's Hospital Medical Center, Cincinnati

Tracking Information

• First Submitted Date: December 12, 2011
• First Posted Date: January 18, 2012
• Results First Submitted Date: February 26, 2020
• Results First Posted Date: September 1, 2020
• Last Update Posted Date: September 1, 2020
• Study Start Date: August 2012
• Actual Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: August 31, 2020)

• Change in Time (Minutes) to Discontinuation of Exercise During a Standardized Treadmill Exercise Test [ Time Frame: Baseline, 7 months ]
  A modified Bruce protocol stress test was used to evaluate improvement in blood oxygen saturation (SpO2). A pulse-oximeter was placed on the participant's finger with the participant at rest while sitting in a chair. Leads for the electrocardiograph were placed on the chest wall. The treadmill was started at 1.7 miles per hour (mph) and a grade of 0%. At three minute intervals, the speed increased as follows: 1.7 mph, 1.7 mph, 1.7 mph, 2.5 mph, 3.4 mph, 4.2 mph, 5.0 mph, 5.5 mph, 6.0 mph, 6.5 mph, 7.0 mph, and 7.5 mph. The participant stopped the test due to intolerable dyspnea or if the SpO2 fell below 88%.
• Change in Minimum Pulse Oximetry During a Standardized Treadmill Exercise Test [ Time Frame: Baseline, 7 months ]
  A modified Bruce protocol stress test was used to evaluate improvement in blood oxygen saturation (SpO2). A pulse-oximeter was placed on the participant's finger with the participant at rest while sitting in a chair. Leads for the electrocardiograph were placed on the chest wall. The treadmill was started at 1.7 miles per hour (mph) and a grade of 0%. At three minute intervals, the speed increased as follows: 1.7 mph, 1.7 mph, 1.7 mph, 2.5 mph, 3.4 mph, 4.2 mph, 5.0 mph, 5.5 mph, 6.0 mph, 6.5 mph, 7.0 mph, and 7.5 mph. The participant stopped the test due to intolerable dyspnea or if the SpO2 fell below 88%.

• Original Primary Outcome Measures (submitted: January 12, 2012): Time for the oxygen saturation to fall below 88% [ Time Frame: 6 months ]

Current Secondary Outcome Measures (submitted: August 31, 2020)

• Change in Diffusion Capacity for Carbon Monoxide [ Time Frame: Baseline, 7 months ]
  Routine full pulmonary function testing, including spirometry, lung volumes, and DLCO, were performed according to American Thoracic Society guidelines.
• Change in Minimum Pulse Oximetry During a Standardized Exercise Protocol Oximetry [ Time Frame: Baseline, 7 months ]
  Standardized exercise pulse oximetry (SEPO) was used to measure SpO2 at the participant's home on a weekly basis between clinic visits. Briefly, a pulse-oximeter was placed on the finger with the participant at rest sitting in a chair. Three baseline (resting) readings were taken over a period of 1 minute to measure the SpO2 at rest. The participant then began stepping onto and off of the first step of a staircase in the home while holding onto the handrail for safety. Stepping was started by placing the bottom of one foot onto the stair followed by the other foot and then removal of one foot from the stair to the floor followed by the other foot. This procedure was repeated at a frequency of 1 cycle per second for a total of 5 minutes. The participant's parent assisted by noting the saturation data at 1-minute intervals during the test onto the weekly exercise form in the participant's Diary. The participant's saturation data continued to be recorded for 3 minutes after the test.
• Change in Radiographic Evidence of PAP Lung Disease [ Time Frame: Baseline, 7 months ]
  High resolution computed tomography (HRCT) scans were performed using an interval technique, a 1 mm slice was obtained every 20 mm. The slice series were placed so that images were obtained from the pulmonary apices to the lung bases with one of the images located at the level of the carina. The CT parameters were performed at full inspiration and required a lower dose than usual clinical CT scans; 1 mm slices at 20 mm intervals,120 kVp, 60 mAs, rotation time 0.5 second. Images were reconstructed with lung and soft tissue reconstruction kernels (B35F and B60F). The primary analysis was performed using the B60F kernel. Images were read and reported according to Radiology Department protocol. The raw data was recorded on a DVD and sent to CCHMC for centralized reading and lung attenuation analysis.
• Change in Quality of Life [ Time Frame: Baseline, 7 months ]
  The PedsQL quality of life questionnaire is a modular approach to measure health-related quality of life in healthy children and those with acute and chronic health conditions. It is self-administered and completed in less than 5 minutes. It contains 23 items divided into 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. To reverse score, transform the 0-4 scale items to 0-100 as follows: 0=100, 1=75, 2=50, 3=25, 4=0. Higher scores indicate a better Health-Related Quality of Life.To create the Psychosocial Health Summary Score, the mean is computed as the sum of the items over the number of items answered in the Emotional, Social, and School Functioning Scales. The Physical Health Summary Score is the same as the Physical Functioning Scale Score. To create the Total Scale Score, the mean is computed as the sum of all the items over the number of items answered on all the Scales.
• Change in Dyspnea Symptom Score [ Time Frame: Baseline, 7 months ]
  The dyspnea visual analogue scales were used by the patient to record the level of dyspnea by a single mark on a linear scale. The dyspnea scale ranged from 0 to 10, with short of breath all the time equal to 0 and never short of breath equal to 10. A higher score indicated a better dyspnea score.
• Change in Serum Anti-GM-CSF Antibodies Levels [ Time Frame: Baseline and monthly up to 7 months ]
  Serum GM-CSF autoantibody was measured as follows: microtiter plates were incubated (4°C, overnight) with rhGM-CSF, washed in PBS and Tween-20, and incubated (room temperature (RT), 1 hour) with blocking solution. Serum samples were diluted with dilution buffer and aliquots of diluted serum or standard were pipetted into adjacent microtiter wells, incubated at RT for 40 minutes, and then washed with wash buffer. Horseradish peroxidase-conjugated secondary antibody was diluted with dilution buffer and pipetted into each well. Plates were incubated (RT, 0.5 hour) and then washed with wash buffer. Substrate solution was added to each well, plates were incubated (RT, 15 min), and color development was stopped with sulfuric acid. Absorbance at 450 nm was measured using a Benchmark® ELISA plate reader.
• Change in Serum Biomarkers - GM-CSF [ Time Frame: Baseline and monthly up to 7 months ]
  Serum GM-CSF was measured via a commercial ELISA kit from R & D Systems.
• Change in Serum Biomarkers - Surfactant Protein D [ Time Frame: Baseline and monthly up to 7 months ]
  Surfactant protein D (SP-D) was measured via a commercial ELISA kit from Biovender.

Original Secondary Outcome Measures (submitted: January 12, 2012)

• Improvement in pulmonary function [ Time Frame: 6 months ]
• Improvement in exercise tolerance [ Time Frame: 6 months ]
• Improvement in CT scan [ Time Frame: 6 months ]
• Improvement in Quality of Life [ Time Frame: 6 months ]
• Improvement in dyspnea and fatigue [ Time Frame: 6 months ]
• Biomarkers will be assayed to detect changes from baseline values: surfactant protein-D (SP-D), KL-6, CEA), GM-CSF, GM-CSF autoantibodies, macrophage colony stimulating factor (M-CSF), and macrophage inflammatory protein -1 alpha MIP-1alpha. [ Time Frame: 6 months ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
• Official Title: Inhaled Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Hereditary Pulmonary Alveolar Proteinosis (PAP)
• Brief Summary: The purpose of this study is to evaluate the therapeutic efficacy of inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (PAP) due to partial dysfunction of the GM-CSF receptor.
• Detailed Description: Not Provided
• Study Type: Interventional
• Study Phase: Phase 2
• Study Design: Allocation: N/A; Intervention Model: Single Group Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Hereditary Pulmonary Alveolar Proteinosis

Intervention

Drug: Leukine

Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.

Other Name: GM-CSF [Leukine (Sargramostim)]

Study Arms

Experimental: Inhaled Leukine (rhGM-CSF)

Inhaled recombinant human GM-CSF in individuals with hereditary Pulmonary Alveolar Proteinosis (hPAP) due to partial dysfunction of the GM-CSF receptor

Intervention: Drug: Leukine

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: January 12, 2012): 2
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: July 2014
• Actual Primary Completion Date: July 2013 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• A diagnosis of PAP caused by bi-allelic mutations in CSF2RA or CSF2RB associated with impaired GM-CSF-R-alpha or GM-CSF-R-beta function, respectively, resulting in reduced but non-zero GM-CSF signaling
• Able and willing to give written informed consent / assent as necessary
• Clinically stable

Exclusion Criteria:

• Confirmed diagnosis of a disorder of surfactant production caused by bi-allelic mutations in ABCA3, SFTPB, or SFTPC
• Confirmed diagnosis of autoimmune PAP caused by a high level of GM-CSF autoantibody
• Confirmed diagnosis of secondary PAP caused by an underlying clinical disorder known to be associated with the development of PAP, e.g., inhalation of silica or titanium; myelodysplasia and others
• Treatment with any investigational agent in the 3 months prior to enrollment
• History of severe allergic or anaphylactic reactions to GM-CSF or other yeast-derived products
• History of asthma or other reactive airways disease
• Known active, viral, fungal, mycobacterial, or other infection
• A serious medical condition which, in the opinion of the investigator or data and safety monitoring committee, would make the patient unsuitable for the study

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 8 Years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: United States

Administrative Information

• NCT Number: NCT01511068
• Other Study ID Numbers: 2011-0959_CCHMC_IRB
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Children's Hospital Medical Center, Cincinnati
• Original Responsible Party: Same as current
• Current Study Sponsor: Children's Hospital Medical Center, Cincinnati
• Original Study Sponsor: Same as current

Collaborators

• Virginia Commonwealth University
• Genzyme, a Sanofi Company

Investigators

• Principal Investigator: Bruce Trapnell, MD; Children's Hospital Medical Center, Cincinnati
• Principal Investigator: Bruce Rubin, MD, FRCPC; Virginia Commonwealth University

• PRS Account: Children's Hospital Medical Center, Cincinnati
• Verification Date: August 2020